share_log

Allogene Therapeutics Analyst Ratings

Allogene Therapeutics Analyst Ratings

Allogene Therapeutic
Benzinga ·  2023/08/03 07:38
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/03/2023 219.83% EF Hutton → $15 Reiterates Buy → Buy
07/12/2023 283.8% Truist Securities $20 → $18 Maintains Buy
06/26/2023 497.01% Oppenheimer → $28 Assumes → Outperform
06/20/2023 390.41% HC Wainwright & Co. → $23 Reiterates Buy → Buy
06/16/2023 646.27% Canaccord Genuity → $35 Reiterates Buy → Buy
06/05/2023 219.83% JMP Securities → $15 Reiterates → Market Outperform
06/05/2023 219.83% EF Hutton → $15 Reiterates Buy → Buy
05/26/2023 219.83% EF Hutton → $15 Reiterates Buy → Buy
05/05/2023 219.83% JMP Securities $19 → $15 Maintains Outperform
05/05/2023 390.41% HC Wainwright & Co. → $23 Reiterates → Buy
05/04/2023 59.91% Stifel $8 → $7.5 Maintains Hold
05/04/2023 219.83% RBC Capital → $15 Reiterates → Outperform
04/20/2023 390.41% HC Wainwright & Co. → $23 Reiterates → Buy
04/18/2023 305.12% JMP Securities → $19 Reiterates → Market Outperform
04/17/2023 219.83% EF Hutton → $15 Maintains Buy
04/04/2023 390.41% HC Wainwright & Co. $29 → $23 Maintains Buy
03/21/2023 27.93% Bernstein → $6 Initiates Coverage On → Market Perform
03/02/2023 560.98% Goldman Sachs $35 → $31 Maintains Buy
03/02/2023 305.12% JMP Securities $23 → $19 Maintains Market Perform
03/01/2023 369.08% RBC Capital $32 → $22 Maintains Outperform
03/01/2023 497.01% Oppenheimer $32 → $28 Maintains Outperform
03/01/2023 560.98% Goldman Sachs $35 → $31 Maintains Buy
03/01/2023 219.83% EF Hutton → $15 Reiterates → Buy
01/24/2023 134.54% JP Morgan $20 → $11 Upgrades Neutral → Overweight
01/06/2023 155.86% Baird → $12 Upgrades Neutral → Outperform
01/05/2023 219.83% EF Hutton → $15 Initiates Coverage On → Buy
12/12/2022 91.9% B of A Securities → $9 Downgrades Buy → Underperform
11/21/2022 518.34% HC Wainwright & Co. $43 → $29 Maintains Buy
09/22/2022 283.8% B. Riley Securities $21 → $18 Maintains Buy
08/10/2022 646.27% Oppenheimer $40 → $35 Maintains Outperform
08/10/2022 582.3% RBC Capital $35 → $32 Maintains Outperform
08/10/2022 — Raymond James Downgrades Outperform → Market Perform
07/15/2022 582.3% Goldman Sachs $9 → $32 Upgrades Neutral → Buy
06/03/2022 134.54% Baird → $11 Initiates Coverage On → Neutral
05/24/2022 91.9% Goldman Sachs $12 → $9 Maintains Neutral
05/05/2022 177.19% Raymond James $36 → $13 Maintains Outperform
03/07/2022 155.86% Goldman Sachs $20 → $12 Maintains Neutral
12/14/2021 646.27% RBC Capital $45 → $35 Maintains Outperform
10/12/2021 475.69% JMP Securities $53 → $27 Maintains Market Outperform
10/08/2021 — Stifel Downgrades Buy → Hold
10/08/2021 859.49% RBC Capital $55 → $45 Maintains Outperform
10/08/2021 326.44% Goldman Sachs $71 → $20 Downgrades Buy → Neutral
09/24/2021 667.59% Raymond James → $36 Upgrades Market Perform → Outperform
09/23/2021 667.59% Raymond James → $36 Upgrades Market Perform → Outperform
05/20/2021 774.2% Truist Securities $34 → $41 Upgrades Hold → Buy
05/14/2021 1008.74% B. Riley Securities → $52 Initiates Coverage On → Buy
03/01/2021 816.84% HC Wainwright & Co. $40 → $43 Maintains Buy
01/26/2021 816.84% Stifel $33 → $43 Upgrades Hold → Buy
12/10/2020 752.88% HC Wainwright & Co. → $40 Assumes → Buy
10/23/2020 1072.71% RBC Capital → $55 Initiates Coverage On → Outperform
06/12/2020 944.78% HC Wainwright & Co. $55 → $49 Maintains Buy
06/01/2020 1072.71% Oppenheimer $50 → $55 Maintains Outperform
06/01/2020 — Raymond James Downgrades Outperform → Market Perform
05/19/2020 1179.32% Roth Capital → $60 Upgrades Neutral → Buy
05/15/2020 — Guggenheim Upgrades Neutral → Buy
05/14/2020 838.17% Canaccord Genuity $36 → $44 Maintains Buy
05/14/2020 966.1% Oppenheimer $44 → $50 Maintains Outperform
05/14/2020 795.52% HC Wainwright & Co. $35 → $42 Reiterates → Buy
05/14/2020 582.3% SunTrust Robinson Humphrey $29 → $32 Downgrades Buy → Hold
04/13/2020 518.34% SunTrust Robinson Humphrey → $29 Initiates Coverage On → Buy
02/24/2020 475.69% Berenberg → $27 Initiates Coverage On → Hold
12/18/2019 688.91% JMP Securities → $37 Initiates Coverage On → Market Outperform
11/04/2019 667.59% Canaccord Genuity → $36 Initiates Coverage On → Buy
08/09/2019 688.91% BTIG → $37 Initiates Coverage On → Buy
06/05/2019 454.37% Roth Capital → $26 Initiates Coverage On → Neutral
05/31/2019 — Guggenheim Initiates Coverage On → Neutral
05/23/2019 475.69% Stifel → $27 Initiates Coverage On → Hold
05/03/2019 859.49% Oppenheimer → $45 Initiates Coverage On → Outperform
03/29/2019 966.1% Piper Sandler → $50 Initiates Coverage On → Overweight
03/15/2019 752.88% Raymond James → $40 Initiates Coverage On → Outperform
03/14/2019 — William Blair Initiates Coverage On → Outperform
11/05/2018 — Cowen & Co. Initiates Coverage On → Outperform
11/05/2018 518.34% JP Morgan → $29 Initiates Coverage On → Neutral
11/05/2018 560.98% Jefferies → $31 Initiates Coverage On → Buy
11/05/2018 774.2% Goldman Sachs → $41 Initiates Coverage On → Buy
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
08/03/2023 219.83% EF Hutton →$15 重申 購買→購買
07/12/2023 283.8% Truist證券 $20→$18 維護 買
2023/06/26 497.01% 奧本海默 →$28 假設 →跑贏大盤
06/20/2023 390.41% HC Wainwright公司 →$23 重申 購買→購買
06/16/2023 646.27% 卡納科特·格納奇 →$35 重申 購買→購買
06/05/2023 219.83% JMP證券 →$15 重申 →市場跑贏大盤
06/05/2023 219.83% EF Hutton →$15 重申 購買→購買
2023年05月26日 219.83% EF Hutton →$15 重申 購買→購買
05/05/2023 219.83% JMP證券 $19→$15 維護 跑贏大盤
05/05/2023 390.41% HC Wainwright公司 →$23 重申 →購買
05/04/2023 59.91% Stifel $8→$7.5 維護 保持
05/04/2023 219.83% 加拿大皇家銀行資本 →$15 重申 →跑贏大盤
04/20/2023 390.41% HC Wainwright公司 →$23 重申 →購買
04/18/2023 305.12% JMP證券 →$19 重申 →市場跑贏大盤
04/17/2023 219.83% EF Hutton →$15 維護 買
04/04/2023 390.41% HC Wainwright公司 $29→$23 維護 買
03/21/2023 27.93% 伯恩斯坦 →$6 開始承保 →市場表現
03/02/2023 560.98% 高盛 $35→$31 維護 買
03/02/2023 305.12% JMP證券 $23→$19 維護 市場表現
03/01/2023 369.08% 加拿大皇家銀行資本 $32→$22 維護 跑贏大盤
03/01/2023 497.01% 奧本海默 $32→$28 維護 跑贏大盤
03/01/2023 560.98% 高盛 $35→$31 維護 買
03/01/2023 219.83% EF Hutton →$15 重申 →購買
01/24/2023 134.54% 摩根大通 $20→$11 升級 中性→超重
01/06/2023 155.86% 貝爾德 →$12 升級 中性→表現優異
01/05/2023 219.83% EF Hutton →$15 開始承保 →購買
2022年12月12日 91.9% B of A證券 →$9 評級下調 購買表現不佳的→
2022年11月21日 518.34% HC Wainwright公司 $43→$29 維護 買
09/22/2022 283.8% B.萊利證券 $21→$18 維護 買
2022年08月10日 646.27% 奧本海默 $40→$35 維護 跑贏大盤
2022年08月10日 582.3% 加拿大皇家銀行資本 $35→$32 維護 跑贏大盤
2022年08月10日 - 雷蒙德·詹姆斯 評級下調 跑贏→市場表現
07/15/2022 582.3% 高盛 $9→$32 升級 中性→購買
06/03/2022 134.54% 貝爾德 →$11 開始承保 →中性
2022年05月24日 91.9% 高盛 $12→$9 維護 中性
05/05/2022 177.19% 雷蒙德·詹姆斯 $36→$13 維護 跑贏大盤
03/07/2022 155.86% 高盛 $20→$12 維護 中性
2021年12月14日 646.27% 加拿大皇家銀行資本 $45→$35 維護 跑贏大盤
10/12/2021 475.69% JMP證券 $53→$27 維護 市場表現強於大盤
10/08/2021 - Stifel 評級下調 購買→Hold
10/08/2021 859.49% 加拿大皇家銀行資本 $55→$45 維護 跑贏大盤
10/08/2021 326.44% 高盛 $71→$20 評級下調 購買→中性
09/24/2021 667.59% 雷蒙德·詹姆斯 →$36 升級 市場表現優於→
09/23/2021 667.59% 雷蒙德·詹姆斯 →$36 升級 市場表現優於→
05/20/2021 774.2% Truist證券 $34→$41 升級 持有→購買
2021/05/14 1008.74% B.萊利證券 →$52 開始承保 →購買
03/01/2021 816.84% HC Wainwright公司 $40→$43 維護 買
2021/01/26 816.84% Stifel $33→$43 升級 持有→購買
12/10/2020 752.88% HC Wainwright公司 →$40 假設 →購買
10/23/2020 1072.71% 加拿大皇家銀行資本 →$55 開始承保 →跑贏大盤
2020/06/12 944.78% HC Wainwright公司 $55→$49 維護 買
06/01/2020 1072.71% 奧本海默 $50→$55 維護 跑贏大盤
06/01/2020 - 雷蒙德·詹姆斯 評級下調 跑贏→市場表現
2020/05/19 1179.32% 羅斯資本 →$60 升級 中性→購買
2020/05/15 - 古根海姆 升級 中性→購買
2020/05/14 838.17% 卡納科特·格納奇 $36→$44 維護 買
2020/05/14 966.1% 奧本海默 $44→$50 維護 跑贏大盤
2020/05/14 795.52% HC Wainwright公司 $35→$42 重申 →購買
2020/05/14 582.3% SunTrust Robinson Humphrey $29→$32 評級下調 購買→Hold
04/13/2020 518.34% SunTrust Robinson Humphrey →$29 開始承保 →購買
02/24/2020 475.69% 貝倫伯格 →$27 開始承保 →保留
2019年12月18日 688.91% JMP證券 →$37 開始承保 →市場跑贏大盤
2019/11/04 667.59% 卡納科特·格納奇 →$36 開始承保 →購買
2019年08月09日 688.91% BTIG →$37 開始承保 →購買
2019年05月06日 454.37% 羅斯資本 →$26 開始承保 →中性
2019年05月31日 - 古根海姆 開始承保 →中性
2019年05月23日 475.69% Stifel →$27 開始承保 →保留
2019年05月03日 859.49% 奧本海默 →$45 開始承保 →跑贏大盤
2019/03/29 966.1% 派珀·桑德勒 →$50 開始承保 →超重
2019年03月15日 752.88% 雷蒙德·詹姆斯 →$40 開始承保 →跑贏大盤
2019/03/14 - 威廉·布萊爾 開始承保 →跑贏大盤
2018年11月05日 - 考恩公司 開始承保 →跑贏大盤
2018年11月05日 518.34% 摩根大通 →$29 開始承保 →中性
2018年11月05日 560.98% 傑富瑞 →$31 開始承保 →購買
2018年11月05日 774.2% 高盛 →$41 開始承保 →購買

What is the target price for Allogene Therapeutics (ALLO)?

同種異體基因治療(ALLO)的目標價格是多少？

The latest price target for Allogene Therapeutics (NASDAQ: ALLO) was reported by EF Hutton on August 3, 2023. The analyst firm set a price target for $15.00 expecting ALLO to rise to within 12 months (a possible 219.83% upside). 32 analyst firms have reported ratings in the last year.

2023年8月3日，EF Hutton報道了異基因治療公司(納斯達克：ALLO)的最新目標價。這家分析公司將目標價定為15美元，預計Allo將在12個月內上漲至(可能上漲219.83%)。去年有32家分析公司公佈了評級。

What is the most recent analyst rating for Allogene Therapeutics (ALLO)?

同種異體基因治療公司(Allo)的最新分析師評級是多少？

The latest analyst rating for Allogene Therapeutics (NASDAQ: ALLO) was provided by EF Hutton, and Allogene Therapeutics reiterated their buy rating.

艾爾建治療公司(納斯達克代碼：ALLO)的最新分析師評級由EF Hutton提供，艾爾建治療公司重申其買入評級。

When is the next analyst rating going to be posted or updated for Allogene Therapeutics (ALLO)?

異基因治療公司(Allo)的下一次分析師評級將於何時發佈或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Allogene Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Allogene Therapeutics was filed on August 3, 2023 so you should expect the next rating to be made available sometime around August 3, 2024.

分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與異種基因治療公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。異基因治療公司的上一次評級是在2023年8月3日提交的，所以你應該預計下一次評級將在2024年8月3日左右的某個時候提供。

Is the Analyst Rating Allogene Therapeutics (ALLO) correct?

分析師對同種異體基因治療公司(Allo)的評級正確嗎？

While ratings are subjective and will change, the latest Allogene Therapeutics (ALLO) rating was a reiterated with a price target of $0.00 to $15.00. The current price Allogene Therapeutics (ALLO) is trading at is $4.69, which is within the analyst's predicted range.

雖然評級是主觀的，並將發生變化，但最新的異基因治療(Allo)評級被重申，目標價在0.00美元至15.00美元之間。異基因治療公司(Allo)目前的交易價格為4.69美元，在分析師的預測範圍內。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論